Novartis

The San Diego Union-Tribune reports on the difficulties health insurers face with new gene and cell therapies.

To the Wrong Cell

Researchers report on a case in which a CAR T-cell therapy was mistakenly delivered to a cancer cell, Stat News writes.

Single-cell RNA sequencing from mouse trachea and human bronchial epithelial cells unearthed new cell types, including ionocytes enriched for CFTR expression.

Risk With the Fix?

Two research teams warn that CRISPR-based gene editing could boost cancer risk by affecting p53 function, according to Stat News.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.

Pages

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.